Live
Endpoints NewsChina biotech’s CRISPR therapy suggests US drugmakers will face competitionBioPharma DiveOricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsEndpoints NewsVivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera optionBioPharma DiveRFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degradersEndpoints NewsBiotech VCs ramp up checks on new bets after years of focusing on existing portfoliosAgilentTRADE NEWS: Agilent Technologies and Shimadzu to Exchange Chromatography Instrument Drivers - YahooLonza NewsLonza Group AG stock: What you should know now for smart investing - AD HOC NEWSBioWorldAurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducersBioWorldNew TRPC6/7 antagonists disclosed in Nyrada patentBioWorldBiologics in development outnumber small molecules for the first timeBioWorldRegeneration in mammals is controlled by environmental conditionsFierceBiotechChina’s Oricell raises $110M for carcinoma CAR-T plans ahead of IPO push
BioWorld Apr 10, 2026

New TRPC6/7 antagonists disclosed in Nyrada patent

New TRPC6/7 antagonists disclosed in Nyrada patent

Original
Body unavailable. Use the original source.

Directory

59 All